France Launches Pilot Program to Boost Senior Vaccination Rates in Loire Region
SAINT-ÉTIENNE, France — The Loire department in central France has been selected as one of four pilot regions to test a new public health initiative aimed at increasing vaccination rates among seniors. The program, known as Prevax 42, seeks to raise vaccination coverage for preventable diseases by 20% among residents aged 65 and older by 2028, according to officials from the Saint-Étienne University Hospital (CHU) and the Auvergne-Rhône-Alpes Gerontopole.
The initiative comes as health authorities warn that vaccination rates among older adults in France remain below recommended levels, leaving many vulnerable to severe complications from preventable illnesses. In the Loire, current vaccination coverage for key diseases such as influenza, COVID-19, and pneumococcal infections falls short of national targets, prompting local health officials to take action.
“Vaccination is one of the most effective ways to age in excellent health,” said Professor Elisabeth Botelho-Nevers, head of the infectious diseases department at CHU Saint-Étienne, during the program’s launch. “It protects older adults not only from the disease itself but also from the complications that can lead to hospitalization and loss of independence.”
Why the Loire?
The Loire department was chosen for the pilot program due to its demographic profile, which includes a higher-than-average proportion of older residents. According to the French National Institute of Statistics and Economic Studies (INSEE), nearly 30% of the Loire’s population is over 60, with 11% aged 75 or older. This aging population makes the region an ideal testing ground for strategies to improve vaccination uptake among seniors.
As of 2026, vaccination rates in the Loire for key diseases among seniors are as follows:
- Influenza: 52.7% (slightly below the national average of 53.4%)
- COVID-19: 30%
- Pneumococcal disease: 9.9%
- Shingles (herpes zoster): Less than 5%
- Respiratory syncytial virus (RSV): Data not publicly available, but health officials emphasize its importance for older adults
The goal of Prevax 42 is to increase influenza vaccination rates to 75% by 2028, a target that aligns with recommendations from the French Public Health Agency (Santé Publique France). The program will also focus on improving coverage for other critical vaccines, though specific targets for those have not been publicly disclosed.
How Prevax 42 Aims to Improve Vaccination Rates
Prevax 42 is designed to address several barriers that may prevent seniors from getting vaccinated. These include lack of awareness, logistical challenges, and vaccine hesitancy. The program will employ a multi-pronged approach, including:
- Community Outreach: Local health workers will engage with seniors in community centers, retirement homes, and senior residences to provide education about the importance of vaccination. This includes addressing common misconceptions and providing clear, evidence-based information about vaccine safety and efficacy.
- Mobile Vaccination Units: To improve accessibility, mobile vaccination clinics will be deployed to rural areas and underserved communities within the Loire. These units will offer vaccines for influenza, COVID-19, pneumococcal disease, and shingles, reducing the need for seniors to travel long distances to healthcare facilities.
- Partnerships with Local Organizations: The program will collaborate with pharmacies, general practitioners, and senior advocacy groups to ensure that vaccination services are widely available and convenient. For example, seniors may be able to receive vaccines during routine medical appointments or at local pharmacies without needing an additional visit.
- Digital Tools: Prevax 42 will leverage digital platforms to send reminders to seniors about upcoming vaccinations, as well as provide information about where and how to get vaccinated. This may include SMS alerts, email notifications, or a dedicated app for tracking vaccination status.
- Incentives and Support: While financial incentives are not currently part of the program, officials are exploring non-monetary ways to encourage vaccination, such as offering transportation assistance or partnering with local businesses to provide discounts or perks for vaccinated seniors.
“The key to success is making vaccination as easy and accessible as possible,” said a spokesperson for the Auvergne-Rhône-Alpes Gerontopole. “Many seniors desire to protect their health, but they may face obstacles like transportation or confusion about which vaccines they need. Prevax 42 is designed to remove those barriers.”
The Broader Context: Vaccination Gaps Among Seniors in France
The Prevax 42 initiative reflects growing concerns among public health officials about vaccination gaps among older adults in France. While vaccination rates for children and adolescents are generally high, coverage among seniors has lagged, particularly for diseases like pneumococcal infections and shingles. This disparity is not unique to France; many countries struggle to achieve high vaccination rates among older populations due to factors such as vaccine hesitancy, logistical challenges, and lack of awareness.
Influenza, for example, remains a significant public health concern for seniors. According to Santé Publique France, influenza and its complications lead to thousands of hospitalizations and deaths among older adults each year. Vaccination is the most effective way to reduce the risk of severe illness, yet coverage rates have stagnated in recent years.
Similarly, pneumococcal disease — which can cause pneumonia, meningitis, and bloodstream infections — poses a serious threat to seniors, particularly those with underlying health conditions. Despite the availability of effective vaccines, coverage remains low. The same is true for shingles, a painful condition caused by the reactivation of the varicella-zoster virus (the same virus that causes chickenpox). The shingles vaccine is highly effective at preventing the disease and its complications, yet fewer than 5% of eligible seniors in the Loire have received it.
COVID-19 vaccination rates among seniors have also declined since the height of the pandemic. While initial uptake was high, booster coverage has dropped, leaving many older adults vulnerable to new variants. Health officials emphasize that COVID-19 remains a serious risk for seniors, particularly those with chronic health conditions, and that staying up to date with vaccinations is critical for protection.
What’s Next for Prevax 42?
The Prevax 42 program is set to run through 2028, with regular evaluations to assess its effectiveness. Health officials will track vaccination rates in the Loire and compare them to those in other regions to determine the impact of the initiative. If successful, the program could serve as a model for other departments in France and beyond.
In the coming months, the program will focus on rolling out mobile vaccination units and launching community outreach efforts. Seniors in the Loire can expect to spot increased information about vaccines in local media, as well as opportunities to receive vaccinations at convenient locations such as pharmacies and senior residences.
For those interested in learning more about Prevax 42 or finding vaccination sites in the Loire, official updates will be available on the Loire department’s official website and through local healthcare providers.
Key Takeaways
- Pilot Program: The Loire department is one of four regions in France testing Prevax 42, a new initiative to increase vaccination rates among seniors aged 65 and older by 20% by 2028.
- Current Vaccination Rates: In the Loire, vaccination coverage for influenza is 52.7%, COVID-19 is 30%, pneumococcal disease is 9.9%, and shingles is less than 5%.
- Goals: The program aims to raise influenza vaccination rates to 75% by 2028 and improve coverage for other key vaccines.
- Strategies: Prevax 42 will use community outreach, mobile vaccination units, partnerships with local organizations, digital tools, and non-monetary incentives to increase vaccination uptake.
- Demographics: Nearly 30% of the Loire’s population is over 60, making it an ideal region for testing strategies to improve senior vaccination rates.
- Broader Impact: If successful, the program could serve as a model for other regions in France and internationally.
FAQ
Why is the Loire department focusing on senior vaccination?
The Loire has a higher-than-average proportion of older residents, with nearly 30% of its population aged 60 or older. This demographic profile makes it an ideal region to test strategies for improving vaccination rates among seniors, who are at greater risk of severe complications from preventable diseases.
What vaccines are included in the Prevax 42 program?
The program focuses on vaccines for influenza, COVID-19, pneumococcal disease, shingles, and respiratory syncytial virus (RSV). These vaccines are recommended for older adults to protect against serious illness and complications.
How can seniors in the Loire get vaccinated?
Seniors in the Loire can receive vaccines through their general practitioners, local pharmacies, mobile vaccination units, and community outreach events. The program aims to make vaccination as convenient and accessible as possible.
What are the goals of Prevax 42?
The primary goal of Prevax 42 is to increase vaccination rates among seniors in the Loire by 20% by 2028. Specifically, the program aims to raise influenza vaccination coverage to 75% within that timeframe.
How will the success of Prevax 42 be measured?
Health officials will track vaccination rates in the Loire and compare them to those in other regions. Regular evaluations will assess the program’s impact and determine whether We see meeting its goals.
What happens if the program is successful?
If Prevax 42 proves effective, it could serve as a model for similar initiatives in other departments in France and internationally. The strategies tested in the Loire may be adapted and implemented in regions facing similar challenges with senior vaccination rates.
Conclusion
The Prevax 42 program represents a proactive step by French health authorities to address vaccination gaps among older adults. By focusing on accessibility, education, and community engagement, the initiative aims to protect seniors from preventable diseases and improve their overall health and independence. As the program unfolds, its progress will be closely watched by public health experts both in France and abroad.
For the latest updates on Prevax 42, readers can visit the Loire department’s official website or consult their local healthcare providers. Have you or a loved one participated in a vaccination program like Prevax 42? Share your thoughts and experiences in the comments below, and help spread the word about the importance of senior vaccination.